ECM
TERN

ExodusPoint Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

ExodusPoint Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.09M Buy
+153,400
New +$6.3M 0.06% 286

Other funds holding TERN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Holocene Advisors
Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

ExodusPoint Capital Management's TERN Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Terns Pharmaceuticals (TERN) stake by 79% in Q1 2026, selling an estimated $12.1M and leaving 80,245 shares worth $4.23M. The position accounts for 0.03% of the portfolio, ranked #492.

ExodusPoint Capital Management first reported a position in TERN in Q4 2023 and has held it in 6 quarters since. The position peaked at $15.2M in Q4 2025. 317 funds tracked by Wall St. Rank hold TERN as of Q1 2026.

  • ExodusPoint Capital Management held 80,245 shares of Terns Pharmaceuticals worth $4.23M as of Q1 2026.
  • ExodusPoint Capital Management sold 295,428 Terns Pharmaceuticals shares in Q1 2026, an estimated $12.1M.
  • Terns Pharmaceuticals made up 0.03% of ExodusPoint Capital Management's portfolio in Q1 2026, its #492 holding.
  • ExodusPoint Capital Management first reported a position in Terns Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
  • ExodusPoint Capital Management's Terns Pharmaceuticals position peaked at $15.2M in Q4 2025.
  • 317 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.